Evidence map›Paper›PMID 40066067›Full record

ReviewFrontiers in cellular and infection microbiology2025

Antivirotics based on defective interfering particles: emerging concepts and challenges.

S V Maryanchik, S E Borovikova, A O Ivanova, V V Trofimov, O E Bagrova, A S Frolova, O N Mityaeva, P Yu Volchkov, A A Deviatkin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

S V MaryanchikInstitute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow, Russia.
S E BorovikovaInstitute of Gene Biology Russian Academy of Sciences (RAS), Moscow, Russia.
A O IvanovaFaculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
V V TrofimovEndocrinology Research Centre, Moscow, Russia.
O E BagrovaState Virus Collection Laboratory, Federal State Budget Institution "National Research Centre for Epidemiology and Microbiology named after Honorary Academician N F Gamaleya" of the Ministry of Health of the Russian Federation, Moscow, Russia.
A S FrolovaSechenov First Moscow State Medical University, Moscow, Russia.
O N MityaevaFederal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia.
P Yu Volchkov *Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia.
A A Deviatkin *Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Viruses are obligate parasites, that use the host's internal metabolic systems for their own reproduction. This complicates the search for molecular targets to prevent the spread of viral infection without disrupting the vital functions of human cells. Defective interfering particles (DIPs) are natural competitors of viruses for important resources of viral reproduction. DIPs emerge during infection, originate from the normal viral replication process and inhibit its progression, making them an interesting candidate for antiviral therapy. Here we describe the biology of DIPs, advances in DIP-based antiviral technology, analyze their therapeutic potential and provide a systemic overview of existing preventive and therapeutic antiviral strategies.

Indexed as

Antiviral AgentsDefective VirusesVirus DiseasesAnimalsHumansVirus ReplicationAntiviral Agentsantiviral therapycoxsackievirusdefective interfering particlesNipah viruspoliovirusSARS-CoV-2viruses

Identifiers

PMID40066067
PMCPMC11891348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.